{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:59:00Z","timestamp":1781819940425,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Secondary prevention clinical trials for Alzheimer\u2019s disease (AD) target amyloid accumulation in asymptomatic, amyloid-positive individuals, but it is unclear to what extent other pathophysiological processes, such as small vessel cerebrovascular disease, account for participant performance on the primary cognitive outcomes in those trials. White matter hyperintensities are areas of increased signal on T2-weighted magnetic resonance imaging (MRI) that reflect small vessel cerebrovascular disease. They are associated with cognitive functioning in older adults and with clinical presentation and course of AD, particularly when distributed in posterior brain regions. The purpose of this study was to examine to what degree regional WMH volume is associated with performance on the primary cognitive outcome measure in the Anti-Amyloid Treatment in Asymptomatic Alzheimer\u2019s Disease (A4) study, a secondary prevention trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data from 1791 participants (59.5% women, mean age (SD) 71.6 (4.74)) in the A4 study and the Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) companion study at the screening visit were used to quantify WMH volumes on T2-weighted fluid-attenuated inversion recovery (FLAIR) MR images. Cognition was assessed with the preclinical Alzheimer cognitive composite (PACC). We tested the association of total and regional WMH volumes with PACC performance, adjusting for age, education, and amyloid positivity status, with general linear models. We also considered interactions between WMH and amyloid positivity status.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Increased frontal and parietal lobe WMH volume was associated with poorer performance on the PACC. While amyloid positivity was also associated with lower cognitive test scores, WMH volumes did not interact with amyloid positivity status.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These results highlight the potential of small vessel cerebrovascular disease to drive AD-related cognitive profiles. Measures of small vessel cerebrovascular disease should be considered when evaluating outcome in trials, both as potential effect modifiers and as a possible target for intervention or prevention.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-024-01395-x","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T07:02:22Z","timestamp":1706857342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Small vessel cerebrovascular disease is associated with cognition in prospective Alzheimer\u2019s clinical trial participants"],"prefix":"10.1186","volume":"16","author":[{"given":"Clarissa D.","family":"Morales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejania","family":"Cotton-Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Lao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia F.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Pyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad J.","family":"Alshikho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael V.","family":"Lippert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsang","family":"Bista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Hale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie C.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay C.","family":"Igwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kacie","family":"Deters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly E.","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Brickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"key":"1395_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack","year":"2013","unstructured":"Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207\u201316.","journal-title":"Lancet Neurol"},{"key":"1395_CR2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science. 1992;256:184\u20135.","journal-title":"Science"},{"key":"1395_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"1395_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1750-3639.2005.tb00104.x","volume":"15","author":"TE Golde","year":"2006","unstructured":"Golde TE. The A\u03b2 hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol. 2006;15:84\u20137.","journal-title":"Brain Pathol"},{"key":"1395_CR5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367:795\u2013804.","journal-title":"N Engl J Med"},{"key":"1395_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n156","volume":"372","author":"SF Ackley","year":"2021","unstructured":"Ackley SF, Zimmerman SC, Brenowitz WD, et al. Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. BMJ. 2021;372: n156.","journal-title":"BMJ"},{"key":"1395_CR7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3233\/JAD-230099","volume":"94","author":"KP Kepp","year":"2023","unstructured":"Kepp KP, Sensi SL, Johnsen KB, et al. The anti-amyloid monoclonal antibody lecanemab: 16 cautionary notes. JAD. 2023;94:497\u2013507.","journal-title":"JAD"},{"key":"1395_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007941","author":"RA Sperling","year":"2014","unstructured":"Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, Aisen P. The A4 study: stopping ad before symptoms begin? Sci Transl Med. 2014. https:\/\/doi.org\/10.1126\/scitranslmed.3007941.","journal-title":"Sci Transl Med"},{"key":"1395_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"1395_CR10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512.","journal-title":"JAMA"},{"key":"1395_CR11","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/alz.12213","volume":"17","author":"DS Knopman","year":"2021","unstructured":"Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimer\u2019s Dementia. 2021;17:696\u2013701.","journal-title":"Alzheimer\u2019s Dementia"},{"key":"1395_CR12","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1001\/jamaneurol.2021.3404","volume":"78","author":"JJ Manly","year":"2021","unstructured":"Manly JJ, Glymour MM. What the aducanumab approval reveals about Alzheimer disease research. JAMA Neurol. 2021;78:1305\u20136.","journal-title":"JAMA Neurol"},{"key":"1395_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00401-017-1717-7","volume":"134","author":"A Kapasi","year":"2017","unstructured":"Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 2017;134:171\u201386.","journal-title":"Acta Neuropathol"},{"key":"1395_CR14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nrneurol.2015.10","volume":"11","author":"ND Prins","year":"2015","unstructured":"Prins ND, Scheltens P. White matter hyperintensities, cognitive impairment and dementia: an update. Nat Rev Neurol. 2015;11:157\u201365.","journal-title":"Nat Rev Neurol"},{"key":"1395_CR15","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1001\/archneurol.2012.1527","volume":"69","author":"AM Brickman","year":"2012","unstructured":"Brickman AM, Provenzano FA, Muraskin J, Manly JJ, Blum S, Apa Z, Stern Y, Brown TR, Luchsinger JA, Mayeux R. Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol. 2012;69:1621\u20137.","journal-title":"Arch Neurol"},{"key":"1395_CR16","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/ana.24647","volume":"79","author":"S Lee","year":"2016","unstructured":"Lee S, Viqar F, Zimmerman ME, et al. White matter hyperintensities are a core feature of Alzheimer\u2019s disease: evidence from the dominantly inherited Alzheimer network. Ann Neurol. 2016;79:929\u201339.","journal-title":"Ann Neurol"},{"key":"1395_CR17","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/ana.25905","volume":"88","author":"PJ Lao","year":"2020","unstructured":"Lao PJ, Gutierrez J, Keator D, et al. Alzheimer-related cerebrovascular disease in Down syndrome. Ann Neurol. 2020;88:1165\u201377.","journal-title":"Ann Neurol"},{"key":"1395_CR18","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1001\/archneur.65.9.1202","volume":"65","author":"AM Brickman","year":"2008","unstructured":"Brickman AM, Honig LS, Scarmeas N, Tatarina O, Sanders L, Albert MS, Brandt J, Blacker D, Stern Y. Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. Arch Neurol. 2008;65:1202\u20138.","journal-title":"Arch Neurol"},{"key":"1395_CR19","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","volume":"389","author":"RA Sperling","year":"2023","unstructured":"Sperling RA, Donohue MC, Raman R, et al. Trial of solanezumab in preclinical Alzheimer\u2019s disease. N Engl J Med. 2023;389:1096\u2013107.","journal-title":"N Engl J Med"},{"key":"1395_CR20","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","volume":"71","author":"MC Donohue","year":"2014","unstructured":"Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, Weiner M, Aisen PS. The preclinical Alzheimer cognitive composite. JAMA Neurol. 2014;71:961\u201370.","journal-title":"JAMA Neurol"},{"key":"1395_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/87565648709540361","volume":"3","author":"E Grober","year":"1987","unstructured":"Grober E, Buschke H. Genuine memory deficits in dementia. Dev Neuropsychol. 1987;3:13\u201336.","journal-title":"Dev Neuropsychol"},{"key":"1395_CR22","unstructured":"Wechsler D. WMS-R: Wechsler Memory Scale--Revised\u202f: manual. Psychological Corporation. 1987"},{"key":"1395_CR23","unstructured":"Wechsler D. WAIS-R manual: Wechsler Adult Intelligence Scale-Revised. Psychological Corporation. 1981"},{"key":"1395_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189\u201398.","journal-title":"J Psychiatr Res"},{"key":"1395_CR25","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.2967\/jnumed.114.153494","volume":"56","author":"AD Joshi","year":"2015","unstructured":"Joshi AD, Pontecorvo MJ, Lu M, Skovronsky DM, Mintun MA, Devous MD. A semiautomated method for quantification of F 18 florbetapir PET images. J Nucl Med. 2015;56:1736\u201341.","journal-title":"J Nucl Med"},{"key":"1395_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.mri.2021.10.007","volume":"85","author":"KC Igwe","year":"2022","unstructured":"Igwe KC, Lao PJ, Vorburger RS, Banerjee A, Rivera A, Chesebro A, Laing K, Manly JJ, Brickman AM. Automatic quantification of white matter hyperintensities on T2-weighted fluid attenuated inversion recovery magnetic resonance imaging. Magn Reson Imaging. 2022;85:71\u20139.","journal-title":"Magn Reson Imaging"},{"key":"1395_CR27","unstructured":"Admiraal-Behloul F, Olofesen H, Van den Heuvel D, Schmitz N, Reiber J, Van Buchem M. Fully automated lobe delineation for regional white matter lesion load quantification in a large scale study. Proc Int Soc Magnet Res Med. 2004"},{"key":"1395_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.neurobiolaging.2014.07.019","volume":"36","author":"AM Brickman","year":"2015","unstructured":"Brickman AM, Zahodne LB, Guzman VA, et al. Reconsidering harbingers of dementia: progression of parietal lobe white matter hyperintensities predicts Alzheimer\u2019s disease incidence. Neurobiol Aging. 2015;36:27\u201332.","journal-title":"Neurobiol Aging"},{"key":"1395_CR29","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1177\/0271678X20957604","volume":"41","author":"L P\u00e5lhaugen","year":"2021","unstructured":"P\u00e5lhaugen L, Sudre CH, Tecelao S, et al. Brain amyloid and vascular risk are related to distinct white matter hyperintensity patterns. J Cereb Blood Flow Metab. 2021;41:1162\u201374.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1395_CR30","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006780","author":"J Graff-Radford","year":"2019","unstructured":"Graff-Radford J, Botha H, Rabinstein AA, et al. Cerebral microbleeds: prevalence and relationship to amyloid burden. Neurology. 2019. https:\/\/doi.org\/10.1212\/WNL.0000000000006780.","journal-title":"Neurology"},{"key":"1395_CR31","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1093\/brain\/aws113","volume":"135","author":"R Ossenkoppele","year":"2012","unstructured":"Ossenkoppele R, Zwan MD, Tolboom N, et al. Amyloid burden and metabolic function in early-onset Alzheimer\u2019s disease: parietal lobe involvement. Brain. 2012;135:2115\u201325.","journal-title":"Brain"},{"key":"1395_CR32","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1093\/brain\/awac229","volume":"145","author":"JA Tanner","year":"2022","unstructured":"Tanner JA, Iaccarino L, Edwards L, et al. Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer\u2019s disease. Brain. 2022;145:4489\u2013505.","journal-title":"Brain"},{"key":"1395_CR33","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s12640-010-9175-1","volume":"18","author":"JL Whitwell","year":"2010","unstructured":"Whitwell JL. Progression of atrophy in Alzheimer\u2019s disease and related disorders. Neurotox Res. 2010;18:339\u201346.","journal-title":"Neurotox Res"},{"key":"1395_CR34","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/alz.12410","volume":"18","author":"A Garnier-Crussard","year":"2022","unstructured":"Garnier-Crussard A, Bougacha S, Wirth M, et al. White matter hyperintensity topography in Alzheimer\u2019s disease and links to cognition. Alzheimers Dement. 2022;18:422\u201333.","journal-title":"Alzheimers Dement"},{"key":"1395_CR35","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/YCO.0000000000000395","volume":"31","author":"R Koncz","year":"2018","unstructured":"Koncz R, Sachdev PS. Are the brain\u2019s vascular and Alzheimer pathologies additive or interactive? Curr Opin Psychiatry. 2018;31:147\u201352.","journal-title":"Curr Opin Psychiatry"},{"key":"1395_CR36","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3390\/brainsci13020218","volume":"13","author":"DG Ali","year":"2023","unstructured":"Ali DG, Abner EL, Bahrani AA, El Khouli R, Gold BT, Jiang Y, Wilcock DM, Jicha GA. Amyloid-PET and white matter hyperintensities have independent effects on baseline cognitive function and synergistic effects on longitudinal executive function. Brain Sci. 2023;13:218.","journal-title":"Brain Sci"},{"key":"1395_CR37","doi-asserted-by":"publisher","first-page":"fcaa132","DOI":"10.1093\/braincomms\/fcaa132","volume":"2","author":"KK Laing","year":"2020","unstructured":"Laing KK, Simoes S, Baena-Caldas GP, et al. Cerebrovascular disease promotes tau pathology in Alzheimer\u2019s disease. Brain Commun. 2020;2:fcaa132.","journal-title":"Brain Commun."},{"key":"1395_CR38","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146:4414\u201324.","journal-title":"Brain"},{"key":"1395_CR39","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1002\/alz.13057","volume":"19","author":"A Garnier-Crussard","year":"2023","unstructured":"Garnier-Crussard A, Cotton F, Krolak-Salmon P, Ch\u00e9telat G. White matter hyperintensities in Alzheimer\u2019s disease: beyond vascular contribution. Alzheimers Dement. 2023;19:3738\u201348.","journal-title":"Alzheimers Dement"},{"key":"1395_CR40","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jamaneurol.2023.3618","volume":"80","author":"Z Shirzadi","year":"2023","unstructured":"Shirzadi Z, Schultz SA, Yau W-YW, et al. Etiology of white matter hyperintensities in autosomal dominant and sporadic Alzheimer disease. JAMA Neurol. 2023;80:1353\u201363.","journal-title":"JAMA Neurol"},{"key":"1395_CR41","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1002\/alz.13371","volume":"19","author":"AM Brickman","year":"2023","unstructured":"Brickman AM, Rizvi B. White matter hyperintensities and Alzheimer\u2019s disease: an alternative view of an alternative hypothesis. Alzheimer\u2019s Dementia. 2023;19:4260\u20131.","journal-title":"Alzheimer\u2019s Dementia"},{"key":"1395_CR42","doi-asserted-by":"publisher","first-page":"e1491","DOI":"10.1212\/WNL.0000000000011599","volume":"96","author":"KD Deters","year":"2021","unstructured":"Deters KD, Napolioni V, Sperling RA, Greicius MD, Mayeux R, Hohman T, Mormino EC. Amyloid PET imaging in self-identified non-Hispanic Black participants of the anti-amyloid in asymptomatic Alzheimer\u2019s disease (A4) study. Neurology. 2021;96:e1491\u2013500.","journal-title":"Neurology"},{"key":"1395_CR43","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/archneur.65.8.1053","volume":"65","author":"AM Brickman","year":"2008","unstructured":"Brickman AM, Schupf N, Manly JJ, et al. Brain morphology in older African Americans, Caribbean Hispanics, and Whites from northern Manhattan. Arch Neurol. 2008;65:1053\u201361.","journal-title":"Arch Neurol"},{"key":"1395_CR44","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2174\/1567205012666150530203214","volume":"12","author":"LB Zahodne","year":"2015","unstructured":"Zahodne LB, Manly JJ, Narkhede A, Griffith EY, DeCarli C, Schupf NS, Mayeux R, Brickman AM. Structural MRI predictors of late-life cognition differ across African Americans, Hispanics, and Whites. Curr Alzheimer Res. 2015;12:632\u20139.","journal-title":"Curr Alzheimer Res"},{"key":"1395_CR45","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.neurobiolaging.2022.11.012","volume":"122","author":"C Morrison","year":"2023","unstructured":"Morrison C, Dadar M, Manera AL, Collins DL. Racial differences in white matter hyperintensity burden in older adults. Neurobiol Aging. 2023;122:112\u20139.","journal-title":"Neurobiol Aging"},{"key":"1395_CR46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1474-4422(17)30431-3","volume":"17","author":"M Kivipelto","year":"2018","unstructured":"Kivipelto M, Mangialasche F, Ngandu T, World Wide Fingers Network. World Wide FINGERS will advance dementia prevention. Lancet Neurol. 2018;17:27.","journal-title":"Lancet Neurol."},{"key":"1395_CR47","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/alz.12123","volume":"16","author":"M Kivipelto","year":"2020","unstructured":"Kivipelto M, Mangialasche F, Snyder HM, et al. World-Wide FINGERS network: a global approach to risk reduction and prevention of dementia. Alzheimers Dement. 2020;16:1078\u201394.","journal-title":"Alzheimers Dement"},{"key":"1395_CR48","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13024-021-00467-y","volume":"16","author":"E McDade","year":"2021","unstructured":"McDade E, Llibre-Guerra JJ, Holtzman DM, Morris JC, Bateman RJ. The informed road map to prevention of Alzheimer disease: a call to arms. Mol Neurodegener. 2021;16:49.","journal-title":"Mol Neurodegener"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01395-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-024-01395-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-024-01395-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T11:14:22Z","timestamp":1707131662000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-024-01395-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,2]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1395"],"URL":"https:\/\/doi.org\/10.1186\/s13195-024-01395-x","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,2]]},"assertion":[{"value":"11 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a secondary data analysis of a publicly available dataset from the screening visit of the A4 trial. The A4 trial received ethics approval by Institutional Review Boards in accordance with International Council for Harmonisation Good Clinical Practice guidelines at each of the 67 trial sites in Australia, Canada, Japan, and the USA, and all participants gave written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Brickman is an inventor on a patent for quantification of white matter hyperintensities. He is a scientific advisor for Cognition Therapeutics, Inc; CogState; and Cognito Therapeutics, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}